bioRxiv · 10.1101/2021.08.18.456891
Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens
Abstract
Global control of COVID-19 will require the deployment of vaccines capable of inducing long-term protective immunity against SARS-CoV-2 variants. In this report, we describe an adjuvanted subunit candidate vaccine that affords elevated, sustained and cross-variant SARS-CoV-2 neutralising antibodies (NAbs) in multiple animal models. Alhydroxiquim-II is a TLR7/8 small-molecule agonist chemisorbed on aluminium hydroxide. Vaccination with Alhydroxiquim-II combined with a stabilized, trimeric form of the SARS-CoV-2 spike protein (termed CoVac-II) resulted in high-titre NAbs in mice, with no decay in responses over an 8-month period. NAbs from sera of CoVac-II-immunized mice, horses and rabbits were broadly neutralising against SARS-CoV-2 variants. Boosting long-term CoVac-II-immunized mice with adjuvanted spike protein from the Beta variant markedly increased levels of NAb titres against multiple SARS-CoV-2 variants; notably high titres against the Delta variant were observed. These data strongly support the clinical assessment of Alhydroxiquim-II-adjuvanted spike proteins to protect against SARS-CoV-2 variants of concern.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Counoupas, C., Pino, P., Stella, A., Ashley, C., Lukeman, H., Bhattacharyya, N., Tada, T., Anchisi, S., Metayer, C., Martinis, J., Aggarwal, A., Dcosta, B., Kint, J., Wurm, M., Landau, N., Steain, M., Turville, S., Wurm, F., David, S., Triccas, J. A.. 2021-08-19. Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens. https://doi.org/10.1101/2021.08.18.456891
Cite the original work for its findings. Save a collection to share your selection of sources.